Health & Biotech ASX Health Stocks: Emyria surges another 10pc; cannabis play Vitura delivers record profit February 13, 2023 Emyria (ASX:EMD) says it has secured sufficient clinical-grade MDMA to support its MDMA-assisted therapy for over 70 patients. ScoPo’s Powerplays: ASX health stocks fall but cap raises show money flowing into sector February 10, 2023 ASX health stocks have fallen this week with Healius dropping 15% in the past five days as H1 FY23 results… PharmAust reports extension of survival time and quality of life from MPL trial for dogs with B-cell lymphoma February 10, 2023 Special Report: PharmAust has set up veterinary trial centres in Australia, New Zealand and the United States to evaluate the… CardieX Raises $4.5 million as it gears up for dual US listing as CONNEQT Pulse awaits FDA Clearance February 10, 2023 Special Report: Australian Medtech CardieX has completed a $4.5million placement, continuing the company’s progress in positioning itself for a potential… Dimerix ticks another box in its Action3 Phase-3 FSGS kidney trial February 10, 2023 Special Report: Dimerix has announced another milestone for its pivotal Phase-3 trial with a positive report on a key review… ASX Health Stocks: Argenica rockets by 30pc after showing potential breakthrough on Alzheimer’s February 9, 2023 Argenica Therapeutics (ASX:AGN) has today shown that its lead drug, ARG-007, significantly inhibited one of the main causes of Alzheimers. The chances of Phase 3 success, and the ASX health stocks that are close to a home run February 9, 2023 These are the ASX health stocks who are on the verge of completing Phase III trials. Stockhead reaches out to… Weed Week: Greens reckon legal cannabis could generate $28 billion over a decade February 9, 2023 The Greens say legal cannabis could bring tourism – and money – to regional areas and put an extra $40… ASX Health Stocks: INOVIQ says its breast cancer technology beats currently available tests February 8, 2023 INOVIQ (ASX:IIQ) rose 5% this morning after announcing positive results for its SUBB2M breast cancer test, beating a market product. Creso Pharma subsidiary Halucenex Life Sciences eyes Aussie market entry following landmark TGA decision February 7, 2023 Special Report: Australia has become the first country in the world to officially recognise psychedelics as medicines, which is good… Next» « Previous